Inefficacy of Hydroxychoroquine in Primary Sjögren’s Syndrome: Results of the Joquer Randomized Placebo-Controlled Trial in Primary Sjögren’s Syndrome

Jacques-Eric Gottenberg¹, Philippe Ravaud², Xavier Puechal³, Véronique Le Guern⁴, Jean Sibilia⁵, Vincent Goeb⁶, C. Larroche⁷, JJ Dubost⁸, Stephanie RIST⁹, Alain Saraux¹⁰, Jacques Morel¹¹, Gilles Hayem¹², Eric Hachulla¹³, Aleth Perdriger¹⁴, D. Sene¹⁴, Charles Zarnitsky¹⁵, Elodie Perrodeau¹⁶, D. Batouche¹⁷, V. Furlan¹⁸, Joelle Benessiano¹⁹, Raphaèle Seror²⁰ and Xavier Mariette¹⁸, ¹Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Internal Medicine, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine, Cochin Hospital, Paris, France, ⁵Rheumatology, CHU Hautepierre, Strasbourg, France, ⁶Rheumatology, Rouen University Hospital, Rouen, France, ⁷Hospital University Bobigny, bobigny, France, ⁸Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ⁹Orleans, Rhumatologie, ¹⁰Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ¹¹Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ¹²Rheumatology Unit, Bichat Hospital, Paris, France, ¹³Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁴Rheumatology, Hôpital Sud, Rennes, France, ¹⁵Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁶Epidemiologist, Paris, France, ¹⁷Paris, ¹⁸Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁹Rheumatology, Paris Unervisity Hospital BICHAT, Paris, France, ²⁰Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and hydroxychloroquine

Session Information

Title: ACR Late-breaking Abstract Oral Session

Session Type: Late-Breaking Abstracts

Background/Purpose:

Hydroxychloroquine (HQ, Plaquenil) is often prescribed in patients with primary Sjögren’s syndrome (pSS), notably for arthralgias, synovitis or purpura, but also only for dryness and fatigue. Thus, at enrollment in the “Assessment of Systemic Signs and Evolution of primary Sjögren’s Syndrome”’ (ASSESS) prospective cohort, 56% of the 395 patients had been or were treated with HQ. However, except a crossover trial which included 19 patients, no controlled trial has ever evaluated HQ versus placebo. We therefore conducted a multicenter, randomized, double-blind, placebo-controlled trial (NCT00632866, Randomized Evaluation of hydroxychloroQUine in primary sJOgren’s syndrome, JOQUER).

Methods:

A total of 120 patients with pSS were randomly assigned to receive HQ (400 mg/j) or placebo and were followed up for 24 weeks. All patients fulfilled the European American consensus group criteria. A favorable overall response (primary outcome criteria) was defined as the patient having at least a 30% improvement between weeks 0 and 24 in the values on 2 of 3 patient’s visual analogic scales (VAS) evaluating dryness, pain and fatigue. Secondary end points were the evolution of Eular Sjögren’s Syndrome Disease Activity Index (ESSDAI), Eular Sjögren’s Syndrome Patient-Related Index (ESSPRI), dryness (Schirmer’s test and unstimulated salivary flow), serum gammaglobulin levels, and of questionnaires of quality of life and symptoms (SF-36, HAD, PROFAD, SSI).

Results:

Baseline characteristics of the 120 patients were as following: mean age 55.9 years, 91.7% of women, median disease duration: 5 years, anti-SSA positivity : 55.1%, median ESSDAI: 2, proportion of patients with systemic involvement at enrollment: 30%, median ESSPRI: 6.3.

At 6 months, 19.2% of patients receiving placebo and 19.6% of patients treated with HQ had a favorable overall response (p = 0.9). No significant difference was observed in the evolution of systemic disease activity, dryness, symptoms and quality of life. No significant difference was observed in patients with anti-SSA autoantibodies, high IgG levels, or systemic involvement at enrollment. In patients treated with HQ, a trend towards a decrease of serum IgG was observed (from 14.5 at enrollment to 13.4g/l at week 24 in the HQ arm and from 14.2 to 14.0 g/l in the placebo arm (p= 0.1), as well as a significant decrease of IgM (from 1.3 to 1.1 g/l under HQ and stable level at 1.4 g/l under placebo, p= 0.01). In the HQ arm, all except 1 of the evaluated patients had detectable blood levels of HQ at 6 months. Tolerance of HQ was comparable to placebo.

Conclusion:

The results of this randomized, double-blind, placebo-controlled trial, did not show any evidence of short term efficacy of hydroxychloroquine in pSS. Analyzes are ongoing to determine whether HQ could have a therapeutic interest in some patients with an interferon signature.

Disclosure:

J. E. Gottenberg,
None;

P. Ravaud,
None;

X. Puechal,
None;

V. Le Guern,
None;

J. Sibilia,
None;

V. Goeb,
None;

C. Larroche,
None;

J. Dubost,
None;

S. RIST,
None;

A. Saraux,
None;

J. Morel,
None;

G. Hayem,
None;

E. Hachulla,
None;

A. Perdriger,
None;

D. Sene,
None;

C. Zarnitsky,
None;

E. Perrodeau,
None;

D. Batouche,
None;

V. Furlan,
None;

J. Benessiano,
None;

R. Seror,
None;

X. Mariette,
None.

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inefficacy-of-hydroxychoroquine-in-primary-sjogrens-syndrome-results-of-the-joquer-randomized-placebo-controlled-trial-in-primary-sjogrens-syndrome/